

Pharmaceutical Benefits Advisory Committee

Email: PBAC@health.gov.au

Address all mail to:
PBAC Secretariat
GPO Box 9848
Canberra ACT 2601

DELISTING OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 01 SEPTEMBER 2022

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

Item

PBAC Advice

Eptifibatide

The sponsor requested the delisting of Inegrillin[®] (eptifibatide) from the Pharmaceutical Benefits Scheme.

The PBAC noted the products were being discontinued by the sponsor and that there were available clinical alternatives. The PBAC advised the delisting of this drug would not result in an unmet clinical need.



Judy Tran
Acting Director
PBAC Assessment Section
Office of Health Technology Assessment
Technology Assessment and Access Division
12 August 2022